Tuesday, November 02, 2004

Synthetic red blood cell substitute



Sanguine Corp.'s PHER-O2 is in Trials with Virginia Commonwealth University for the U.S. Navy

"PASADENA, Calif.--(BUSINESS WIRE)--Nov. 1, 2004--Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, today announced that its synthetic red blood cell substitute, PHER-O2, is being used in trials conducted by Virginia Commonwealth University for the U.S. Navy on submarine crew and deep sea diving oxygenation treatment of the bends.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., noted, "In the medical treatment of the bends, the doctor typically will first treat immediate life threats, such as breathing problems or shock, if present. The diver will need high-flow oxygen and IV fluids. Blood and urine will be sent for laboratory tests to assess any blood clotting problems and hydration status. Additionally, the diver will need to go to a hyperbaric chamber for recompression. During this process the chamber becomes pressurized with air and oxygen based on prearranged protocols to simulate pressure depths of 30-60 feet. Typical dives last 140-270 minutes, but may last longer. At this depth or chamber pressures, bubbles are reduced in size or reabsorbed to ensure adequate blood flow. Recompression prevents further bubble formation and provides high amounts of oxygen to the injured tissues. Further treatments depend on how the diver responds to the initial treatment. The work under way with the U.S. Navy and Virginia Commonwealth University is an effort to use PHER-O2 in conjunction with increasing the blood oxygen levels in patients with the bends. One of the goals is to better enable the quick ascent of divers working on military operations."

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors, and hemorrhagic shock. The company is also developing non-medical applications for its perfluorocarbon (PFC) product.


Contacts
Sanguine Corp.
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net
www.sanguine-corp.com